The shift of cannabis from Schedule I to Schedule III by the DEA signals a pivotal move toward federal legalization, enhancing research opportunities and mainstream acceptance.
This reclassification allows for more comprehensive studies on cannabis's impact on chronic pain and other medical conditions, aiding in its prescription and accessibility.
With cannabis now classified under Schedule III, banks are more inclined to offer financial services to cannabis companies, facilitating much-needed banking access and loans.
Cannabis companies will now be eligible for tax deductions akin to other businesses, removing a significant financial obstacle they previously faced.
Collection
[
|
...
]